Recombinant versus natural human 111In-beta2-microglobulin for scintigraphic detection of Abeta2m amyloid in dialysis patients.
BACKGROUND
We previously introduced scintigraphy with 131I-labeled beta2-microglobulin (beta2m), purified from uremic hemofiltrate, that is, "natural" beta2m, to specifically detect beta2m-associated amyloidosis (Abeta2m) in hemodialysis (HD) patients.


METHODS
To improve the safety and resolution of the scan, we covalently bound the chelator diethylenetriaminepentaacetic acid to natural beta2m to allow radiolabeling with 111In. In a second step, we generated and evaluated the usage of recombinant human beta2m (rhbeta2m) for scintigraphy.


RESULTS
Using natural 111In-labeled beta2m, eight patients on HD for 0 to 17 years, without evidence of Abeta2m, were scanned. Whole-body scintigraphy at 48 to 72 hours postinjection revealed no significant tracer accumulation over joint regions. In contrast, nine patients on HD for 10 to 21 years with clinical, radiological, or histologic (N = 4) evidence of Abeta2m showed selective tracer uptake over various joint regions. Tracer accumulation in visceral organs, which could not be related to tracer elimination or metabolism, was not detected. Compared with the previous 131I beta2m scan, scintigraphy with 111In-labeled beta2m offered highly improved image contrast, increased sensitivity, and a 50 to 70% reduction of the radiation exposure. Scanning with 111In-labeled recombinant human beta2m was performed in six patients: No significant tracer accumulation was observed over joint regions in two patients on short-term HD without evidence of Abeta2m; in contrast, local tracer accumulations similar to those observed with natural beta2m could be demonstrated in four long-term (10 to 27 years) HD patients with clinical, radiological, and histologic (N = 1) evidence of Abeta2m.


CONCLUSIONS
Scintigraphy for Abeta2m with 111In-labeled rhbeta2m provides a homogenous and safe recombinant protein source and leads to enhanced sensitivity and lower radiation exposure.
Divisions of Nephrology and Nuclear Medicine, Medical School, Hannover, Germany.
J
J
Schäffer
W
W
Burchert
J
J
Floege
P
P
Gielow
C
C
Kionka
R P
RP
Linke
E H
EH
Weiss
S
S
Shaldon
K M
KM
Koch
D000328:Adult; D000368:Aged; D000686:Amyloidosis / Q000000981:diagnostic imaging*; D005260:Female; D006801:Humans; D007205:Indium Radioisotopes; D007676:Kidney Failure, Chronic / Q000000981:diagnostic imaging* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011829:Radiation Dosage; D011877:Radionuclide Imaging / Q000379:methods; D011994:Recombinant Proteins; D006435:Renal Dialysis; D012680:Sensitivity and Specificity; D014511:Uremia / Q000000981:diagnostic imaging / Q000628:therapy; D001613:beta 2-Microglobulin
D007205:Indium Radioisotopes; D011994:Recombinant Proteins; D001613:beta 2-Microglobulin